Literature DB >> 1675717

Laboratory monitoring of antifungal chemotherapy. British Society for Antimicrobial Chemotherapy Working Party.

.   

Abstract

Mesh：

Substances：

Year:  1991        PMID： 1675717

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

1.  Possible failure of itraconazole in preventing fungal infection in a neutropenic leukaemia patient.

Authors:  W D Hendriks; W Sizoo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

2.  Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: an association with bioavailability of oral solution itraconazole.

Authors:  Takehiko Mori; Yoshinobu Aisa; Jun Kato; Yukinori Nakamura; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2009-05-27       Impact factor: 2.490

3.  Possible interaction between phenobarbital, carbamazepine and itraconazole.

Authors:  M Bonay; A P Jonville-Bera; P Diot; E Lemarie; M Lavandier; E Autret
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

Review 4.  Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections.

Authors:  M Haria; H M Bryson; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

5.  The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study.

Authors:  Yoshikazu Ito; Kazuma Ohyashiki; Isao Yoshida; Makoto Takeuchi; Yasutaka Aoyama; Atsuko Mugitani; Yasuhiro Matsuura; Hisashi Wakita; Mitsuhiro Matsuda; Erina Sakamoto; Toru Kiguchi; Akio Urabe; Kazuo Tamura; Akihisa Kanamaru; Toru Masaoka
Journal:  Int J Hematol       Date:  2007-02       Impact factor: 2.490

6.  Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients.

Authors:  N Troillet; C Durussel; J Bille; M P Glauser; J P Chave
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-12       Impact factor: 3.267

7.  Temporofacial zygomycosis in a pregnant woman.

Authors:  M R Buhl; T P Joseph; B E Snelling; L Buhl
Journal:  Infection       Date:  1992 Jul-Aug       Impact factor: 3.553

Review 8.  Optimisation of itraconazole therapy using target drug concentrations.

Authors:  J M Poirier; G Cheymol
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447

Review 9.  Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.

Authors:  Chris Stockmann; Jonathan E Constance; Jessica K Roberts; Jared Olson; Elizabeth H Doby; Krow Ampofo; Justin Stiers; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

Review 10.  Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.

Authors:  H Ruth Ashbee; Rosemary A Barnes; Elizabeth M Johnson; Malcolm D Richardson; Rebecca Gorton; William W Hope
Journal:  J Antimicrob Chemother       Date:  2013-12-29       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.